InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Hematological Malignancies Drugs Market- by Drugs (Monoclonal Antibodies, Blincyto (Blinatumomab), Besponsa (Inotuzumab Ozogamicin), Lumoxiti (Moxetumomab Pasudotox), Mylotarg (Gemtuzumab Ozogamicin), Opdivo (Nivolumab), AiRuiKa (Camrelizumab), Tyvyt (Sintilimab), Tislelizumab, Gazyva (Obinutuzumab), Zynlonta (Loncastuximab Tesirine-lpyl), Darzalex (Daratumumab), Blenrep (Belantamab Mafodotin-blmf), Keytruda (Pembrolizumab), Adcetris (Brentuximab Vedotin), Arzerra (Ofatumumab), CAR-T Cell Therapy, Tecartus (Brexucabtagene Autoleucel), Kymriah (Tisagenlecleucel), Yescarta (Axicabtagene Ciloleucel), Breyanzi (Lisocabtagene Maraleucel) and Abecma (Idecabtagene Vicleucel)), Pipeline Products (Monoclonal Antibodies, Teclistamab, Iomab-B, Ublituximab, CS1001, CAR-T Cell Therapy and Ciltacabtagene Autoleucel (JNJ-68284528)), Indications (Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoma, Hodgkin’s Lymphoma, Non-Hodgkin’s Lymphoma and Multiple Myeloma), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the global Hematological Malignancies Drugs Market Size is estimated to grow at a CAGR of 14.2% during the forecast period for 2024-2031.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1211
Cancers that damage the bone marrow, lymph nodes, and blood are hematological malignancies. The three hematological cancers include myeloma, leukemia, and lymphoma, with lymphoma being the most prevalent kind. The clinical results for blood cancers have been improved by using small molecule inhibitors, monoclonal antibodies, bispecific T cell engagers, antibody-drug conjugates, recombinant immunotoxins, and Chimeric Antigen Receptor T (CAR-T) cells, among other novel targeted therapies.
Increasing R&D efforts to create novel cancer therapies, adoption of precision medicine in the field of hematological malignancies, an increase in the number of drugs approved for the treatment of various types of hematological malignancies, and growing advancements in leukemia and lymphoma targeted therapies are just a few of the factors contributing to the growth of the hematological malignancies drugs market.
North America is anticipated to be the major contributor to the Hematological Malignancies Drugs market over the forecast years due to the rising rates of leukemia and lymphoma in this area and the rising R&D spending for cancer therapies. In addition, the Asia Pacific regional market is expected to register significant growth during the estimated period. The market is expected to rise due to rising financing for cancer research, a high incidence of blood cancers, and an increased demand for efficient treatments.
Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1211
Major market players operating in the Hematological Malignancies Drugs market include
AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and others.
Recent collaborations and agreements in the market:
- In October 2021, for treating chronic myeloid leukemia (CML), Novartis received the US FDA’s approval of Scemblix (asciminib) for two different indications.
- In September 2021, results from the dose-escalation portion of the Phase 1/2 EPCORE NHL-1 first-in-human (FIH) dose-escalation and cohort expansion clinical trial, which evaluated the safety and early efficacy of the investigational therapy epcoritamab (DuoBody-CD3xCD20) in patients with B-cell non-lymphoma Hodgkin’s that had relapsed or been resistant to treatment, was released by AbbVie and Genma (B-NHL).
Get Specific Chapter/Information From The Report:@ https://www.insightaceanalytic.com/customisation/1211
Market Segments
Global Hematological Malignancies Drugs Market, by Drugs, 2024-2031 (Value US$ Mn)
- Monoclonal Antibodies
- Blincyto (Blinatumomab)
- Besponsa (Inotuzumab Ozogamicin)
- Lumoxiti (Moxetumomab Pasudotox)
- Mylotarg (Gemtuzumab Ozogamicin)
- Opdivo (Nivolumab)
- AiRuiKa (Camrelizumab)
- Tyvyt (Sintilimab)
- Tislelizumab
- Gazyva (Obinutuzumab)
- Zynlonta (Loncastuximab Tesirine-lpyl)
- Darzalex (Daratumumab)
- Blenrep (Belantamab Mafodotin-blmf)
- Keytruda (Pembrolizumab)
- Adcetris (Brentuximab Vedotin)
- Arzerra (Ofatumumab
- CAR-T Cell Therapy
- Tecartus (Brexucabtagene Autoleucel)
- Kymriah (Tisagenlecleucel)
- Yescarta (Axicabtagene Ciloleucel)
- Breyanzi (Lisocabtagene Maraleucel)
- Abecma (Idecabtagene Vicleucel)
Global Hematological Malignancies Drugs Market, by Pipeline Products, 2024-2031 (Value US$ Mn)
- Monoclonal Antibodies
- Teclistamab
- Iomab-B
- Ublituximab
- CS1001
- CAR-T Cell Therapy
- Ciltacabtagene Autoleucel (JNJ-68284528)
Global Hematological Malignancies Drugs Market, by Indications, 2024-2031 (Value US$ Mn)
- Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Lymphoma
- Hodgkin’s Lymphoma
- Non-Hodgkin’s Lymphoma
- Multiple Myeloma
Global Hematological Malignancies Drugs Market, by Region, 2024-2031 (Value US$ Mn)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Hematological Malignancies Drugs Market, by Country, 2024-2031 (Value US$ Mn)
- S.
- Canada
Europe Hematological Malignancies Drugs Market, by Country, 2024-2031 (Value US$ Mn)
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Hematological Malignancies Drugs Market, by Country, 2024-2031 (Value US$ Mn)
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Hematological Malignancies Drugs Market, by Country, 2024-2031 (Value US$ Mn)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Hematological Malignancies Drugs Market, by Country, 2024-2031 (Value US$ Mn)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Get More Information :
https://www.insightaceanalytic.com/report/global-hematological-malignancies-drugs-market–/1211
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
